Table 2. Open in new tab Association of...

Characteristic

Rates of pain reduction, %

OR (95% CI)^a

P^a^,^b

Demographics

Race

Non-Black

53.6

Referent

Black

62.5

1.37 (0.70 to 2.69)

.36

Ethnicity

Not Hispanic

54.8

Referent

Hispanic

47.1

0.79 (0.39 to 1.60)

.52

Age

70 y or older

47.4

Referent

<70 y

55.4

1.37 (0.84 to 2.23)

.21

Height

155 cm or taller

53.9

Referent

<155 cm

60.4

1.44 (0.80 to 2.59)

.22

Weight

75 kg or heavier

52.9

Referent

<75 kg

56.9

1.23 (0.88 to 1.74)

.23

BMI

≥30 kg/m²

54.0

Referent

<30 kg/m²

54.9

1.08 (0.78 to 1.50)

.65

Clinical factors

Total time on AI therapy

≥180 d

51.4

Referent

<180 d

66.1

1.65 (1.08 to 2.53)

.02

Breast cancer stage

I or II

53.7

Referent

III

58.3

1.22 (0.73 to 2.03)

.44

Prior taxane therapy^c

55.0

Referent

Yes

56.0

1.07 (0.73 to 1.59)

.72

Prior bisphosphonates

53.7

Referent

Yes

56.9

1.04 (0.68 to 1.58)

.86

Patient-reported outcomes

BPI average pain

≥5 (more pain)

56.2

Referent

<5 (less pain)

48.6

0.68 (0.46 to 1.01)

.06

BPI worst pain

≥6 (more pain)

53.4

Referent

<6 (less pain)

58.7

1.21 (0.78 to 1.87)

.39

BPI pain interference

≥3 (more pain)

52.7

Referent

<3 (less pain)

59.7

1.45 (0.97 to 2.17)

.07

FACT functional well-being

<24 (worse function)

52.0

Referent

≥24 (better function)

71.0

2.34 (1.34 to 4.07)

.003

FACT physical well-being

<14 (worse function)

38.9

Referent

≥14 (better function)

57.3

2.20 (1.39 to 3.47)

<.001

FACT endocrine subscale

<42 (more symptoms)

47.3

Referent

≥42 (fewer symptoms)

55.3

1.48 (0.90 to 2.44)

.12

WOMAC

≥50 (more pain)

47.9

Referent

<50 (less pain)

63.3

1.79 (1.28 to 2.52)

<.001

M-SACRAH

≥33 (more symptoms)

47.7

Referent

<33 (fewer symptoms)

62.5

1.81 (1.29 to 2.53)

<.001

Table 2.

Open in new tab

Association of baseline characteristics and patient-reported outcomes with at least a 2-point absolute reduction in BPI average pain from baseline to 12 weeks

Characteristic	Rates of pain reduction, %	OR (95% CI)^a	P^a^,^b
Demographics
Race
Non-Black	53.6	Referent
Black	62.5	1.37 (0.70 to 2.69)	.36
Ethnicity
Not Hispanic	54.8	Referent
Hispanic	47.1	0.79 (0.39 to 1.60)	.52
Age
70 y or older	47.4	Referent
<70 y	55.4	1.37 (0.84 to 2.23)	.21
Height
155 cm or taller	53.9	Referent
<155 cm	60.4	1.44 (0.80 to 2.59)	.22
Weight
75 kg or heavier	52.9	Referent
<75 kg	56.9	1.23 (0.88 to 1.74)	.23
BMI
≥30 kg/m²	54.0	Referent
<30 kg/m²	54.9	1.08 (0.78 to 1.50)	.65
Clinical factors
Total time on AI therapy
≥180 d	51.4	Referent
<180 d	66.1	1.65 (1.08 to 2.53)	.02
Breast cancer stage
I or II	53.7	Referent
III	58.3	1.22 (0.73 to 2.03)	.44
Prior taxane therapy^c
No	55.0	Referent
Yes	56.0	1.07 (0.73 to 1.59)	.72
Prior bisphosphonates
No	53.7	Referent
Yes	56.9	1.04 (0.68 to 1.58)	.86
Patient-reported outcomes
BPI average pain
≥5 (more pain)	56.2	Referent
<5 (less pain)	48.6	0.68 (0.46 to 1.01)	.06
BPI worst pain
≥6 (more pain)	53.4	Referent
<6 (less pain)	58.7	1.21 (0.78 to 1.87)	.39
BPI pain interference
≥3 (more pain)	52.7	Referent
<3 (less pain)	59.7	1.45 (0.97 to 2.17)	.07
FACT functional well-being
<24 (worse function)	52.0	Referent
≥24 (better function)	71.0	2.34 (1.34 to 4.07)	.003
FACT physical well-being
<14 (worse function)	38.9	Referent
≥14 (better function)	57.3	2.20 (1.39 to 3.47)	<.001
FACT endocrine subscale
<42 (more symptoms)	47.3	Referent
≥42 (fewer symptoms)	55.3	1.48 (0.90 to 2.44)	.12
WOMAC
≥50 (more pain)	47.9	Referent
<50 (less pain)	63.3	1.79 (1.28 to 2.52)	<.001
M-SACRAH
≥33 (more symptoms)	47.7	Referent
<33 (fewer symptoms)	62.5	1.81 (1.29 to 2.53)	<.001

Characteristic	Rates of pain reduction, %	OR (95% CI)^a	P^a^,^b
Demographics
Race
Non-Black	53.6	Referent
Black	62.5	1.37 (0.70 to 2.69)	.36
Ethnicity
Not Hispanic	54.8	Referent
Hispanic	47.1	0.79 (0.39 to 1.60)	.52
Age
70 y or older	47.4	Referent
<70 y	55.4	1.37 (0.84 to 2.23)	.21
Height
155 cm or taller	53.9	Referent
<155 cm	60.4	1.44 (0.80 to 2.59)	.22
Weight
75 kg or heavier	52.9	Referent
<75 kg	56.9	1.23 (0.88 to 1.74)	.23
BMI
≥30 kg/m²	54.0	Referent
<30 kg/m²	54.9	1.08 (0.78 to 1.50)	.65
Clinical factors
Total time on AI therapy
≥180 d	51.4	Referent
<180 d	66.1	1.65 (1.08 to 2.53)	.02
Breast cancer stage
I or II	53.7	Referent
III	58.3	1.22 (0.73 to 2.03)	.44
Prior taxane therapy^c
No	55.0	Referent
Yes	56.0	1.07 (0.73 to 1.59)	.72
Prior bisphosphonates
No	53.7	Referent
Yes	56.9	1.04 (0.68 to 1.58)	.86
Patient-reported outcomes
BPI average pain
≥5 (more pain)	56.2	Referent
<5 (less pain)	48.6	0.68 (0.46 to 1.01)	.06
BPI worst pain
≥6 (more pain)	53.4	Referent
<6 (less pain)	58.7	1.21 (0.78 to 1.87)	.39
BPI pain interference
≥3 (more pain)	52.7	Referent
<3 (less pain)	59.7	1.45 (0.97 to 2.17)	.07
FACT functional well-being
<24 (worse function)	52.0	Referent
≥24 (better function)	71.0	2.34 (1.34 to 4.07)	.003
FACT physical well-being
<14 (worse function)	38.9	Referent
≥14 (better function)	57.3	2.20 (1.39 to 3.47)	<.001
FACT endocrine subscale
<42 (more symptoms)	47.3	Referent
≥42 (fewer symptoms)	55.3	1.48 (0.90 to 2.44)	.12
WOMAC
≥50 (more pain)	47.9	Referent
<50 (less pain)	63.3	1.79 (1.28 to 2.52)	<.001
M-SACRAH
≥33 (more symptoms)	47.7	Referent
<33 (fewer symptoms)	62.5	1.81 (1.29 to 2.53)	<.001

Odds ratios and P values are stratified by study and adjusted for an indicator variable denoting active agent treatment arm. AI = aromatase inhibitor; BMI = body mass index; BPI = Brief Pain Inventory; CI = confidence interval; FACT = Functional Assessment of Cancer Therapy; M-SACRAH = Modified Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands; OR = odds ratio; Ref = reference; WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index.

Tested using 2-sided Wald χ² tests.

Prior taxane therapy information is not available for participants in S1200.

This Feature Is Available To Subscribers Only